Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan;44(1):1-10.
doi: 10.1016/j.healun.2024.09.021. Epub 2024 Oct 5.

A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension

Thomas M Cascino  1 , Sandeep Sahay  2 , Victor M Moles  3 , Vallerie V McLaughlin  3
Affiliations
Review

A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension

Thomas M Cascino et al. J Heart Lung Transplant. 2025 Jan.

Abstract

Despite increasing therapeutic options and evolving treatment strategies, including targeting 3 therapeutic pathways, in the management of pulmonary arterial hypertension (PAH), morbidity and mortality have remained unacceptably high. Sotatercept is a first-in-class, novel activin signaling inhibitor approved for treating PAH based on evolving efficacy and safety evidence. This state-of-the-art review summarizes the current understanding of the mechanism of action, the impact on outcomes that improve how patients feel, function, and survive, and the safety and adverse event profile to inform readers of this breakthrough novel therapy.

Keywords: outcomes; pulmonary arterial hypertension; sotatercept; survival; treatment.

PubMed Disclaimer

References

    1. Galiè N, Channick RN, Frantz RP, et al.: Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019;53. - PMC - PubMed
    1. Badesch DB, McLaughlin VV, Delcroix M, et al.: Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:56s–61s. - PubMed
    1. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ: Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:62s–7s. - PubMed
    1. Ghofrani HA, Pepke-Zaba J, Barbera JA, et al.: Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:68s–72s. - PubMed
    1. Zelt JGE, Sugarman J, Weatherald J, et al.: Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era. Eur Respir J 2022;59. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources